Radionetics Oncology
Alyssa Levin serves as the Chief Financial Officer at Radionetics Oncology, where the company focuses on innovative precision radiopharmaceuticals for solid tumor treatment. Prior to this role, Alyssa was the Chief Financial and Business Officer at Nkarta, Inc., working on harnessing natural killer cells for cancer therapy, and the Chief Financial Officer at ViaCyte, contributing to stem cell-derived treatments for diabetes. Alyssa co-founded the Frontline Hero Fund to support healthcare workers affected by COVID-19 and has held various CFO positions at Bird Rock Bio, Tentarix Biotherapeutics, and Cosmederm Bioscience. Previous experience also includes a managerial position at PwC, specializing in capital markets advisory for biotech clients. Alyssa holds multiple degrees in accounting, psychology, and economics from recognized institutions, including the University of Saskatchewan and The University of British Columbia.
This person is not in any teams
This person is not in any offices
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.